The Western Europe Cancer Targeted Therapy Market size is expected to reach US$ 50,427.8 million by 2031 from US$ 21,460.8 million in 2024. The market is estimated to record a CAGR of 13.0 % from 2025 to 2031.
The North America cancer targeted therapy market is one of the largest and most advanced globally, driven by rising cancer prevalence, significant healthcare expenditure, and the early adoption of precision medicine. The region primarily includes the US and Canada, both of which have highly developed healthcare infrastructure, access to innovative diagnostics, and strong government and private-sector support for oncology research.
Targeted therapies—including monoclonal antibodies, tyrosine kinase inhibitors, immune checkpoint inhibitors, cancer vaccines, and antibody-drug conjugates (ADCs)—are widely used across the region due to their clinical efficacy and favorable safety profiles. Genomic profiling and biomarker-driven therapy selection have become standard practice, enabling tumor-specific precision treatments that improve survival rates. Hospital pharmacies dominate the distribution of intravenous therapies, while oral-targeted therapies are increasingly accessed through retail and specialty pharmacies.
North America benefits from robust reimbursement frameworks, insurance coverage, and government programs such as the National Cancer Institute (NCI) initiatives in the US, facilitating patient access to high-cost therapies. Multinational and domestic pharmaceutical companies actively collaborate with hospitals, research centers, and clinical trial networks to introduce novel therapies rapidly. The region also serves as a global hub for oncology clinical trials. These factors position North America as a high-value, innovation-driven region for targeted oncology therapies.
Key segments that contributed to the derivation of the North America Cancer Targeted Therapy market analysis are therapy type, indication, and distribution channel.
By therapy type, the cancer targeted therapy market is segmented into monoclonal antibodies, tyrosine kinase inhibitors, immune checkpoint inhibitors, cancer vaccines, gene therapy, and others. The monoclonal antibodies segment dominated the market in 2024. Based on indication, the cancer targeted therapy market is segmented into blood cancer, lung cancer, breast cancer, colorectum cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other indications. The lung cancer segment dominated the market in 2024. In terms of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online stores. The hospital pharmacies segment dominated the market in 2024. Advancing Genomic Profiling to Enable Biomarker Discovery
Advancements in genomic profiling and biomarker discovery are major market drivers. Technologies such as next-generation sequencing (NGS), liquid biopsies, and comprehensive molecular diagnostics allow clinicians to identify genetic alterations such as EGFR, HER2, ALK, BRCA1/2, and PIK3CA mutations. These insights enable precision therapy selection, improving patient outcomes while reducing systemic toxicity associated with conventional chemotherapy.
The US and Canada have highly advanced oncology infrastructure, with widespread adoption of genomic profiling programs in hospitals, cancer centers, and academic institutions. Liquid biopsy technology allows early detection, monitoring of minimal residual disease, and identification of treatment resistance, which extends therapy duration and improves clinical outcomes. Companion diagnostics—increasingly mandated by regulatory agencies for targeted therapies—support patient stratification for clinical trials and real-world application.
Pharmaceutical companies collaborate with hospitals, diagnostic labs, and academic research centers to expand access to biomarker testing and support the development of mutation-specific therapies. The growth of regional genomic databases also accelerates the discovery of novel targets and patient populations suitable for therapy. With strong reimbursement frameworks, insurance coverage, and government-supported precision medicine initiatives, the adoption of targeted therapies in North America is rapidly increasing.
Targeting Rare Cancers Through Genetic Mutation Profiling
The market presents substantial opportunities in developing targeted therapies for rare cancers and tumors with specific genetic mutations. Traditionally underserved due to small patient populations and high development costs, rare cancers can now be addressed through tumor-agnostic therapies targeting actionable mutations such as NTRK fusions, RET rearrangements, BRAF, and FGFR alterations.
Next-generation sequencing and population-level genomic databases allow early identification of patients with rare mutations. Basket and umbrella trial designs reduce development timelines, enabling companies to bring therapies to market efficiently and expand indications across multiple rare malignancies. Orphan drug designations, accelerated approval pathways, and extended market exclusivity provide incentives for companies to invest in rare cancer therapeutics.
Leading pharmaceutical companies—including Roche, Merck, AstraZeneca, Novartis, Bristol-Myers Squibb, and Pfizer—actively collaborate with hospitals, cancer centers, and research networks to expand patient access. Clinical trial programs in the US and Canada allow rapid evaluation of novel targeted therapies and facilitate early adoption in oncology practice. Additionally, patient assistance programs and insurance coverage ensure affordability for high-cost therapies. As precision oncology becomes standard care, an increasing number of patients with mutation-defined cancers are eligible for advanced targeted therapies, strengthening pipelines, diversifying revenue streams, and addressing unmet clinical needs.
The North America Cancer Targeted Therapy market demonstrates steady growth, with size and share analysis highlighting evolving trends and competitive dynamics among key players. The report examines subsegments categorized within therapy type, indication, and distribution channel, offering insights into their contribution to overall market performance.
By therapy type, the monoclonal antibodies subsegment dominated the market in 2024, driven by their high specificity, proven clinical efficacy, and ability to be combined with chemotherapy or immunotherapy.
Based on indication, the lung cancer subsegment dominated the market in 2024, driven by the high prevalence, environmental risk factors (smoking, pollution), and availability of multiple targeted therapies for EGFR, ALK, ROS1, and PD-L1 mutations.
By distribution channel, the hospital pharmacies subsegment dominated the market in 2024, driven by the centralized administration of complex oncology therapies, greater access to specialized oncology care, and hospitals serving as primary sites for cancer diagnosis, treatment initiation, and monitoring.
The "North America Cancer Targeted Therapy Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
North America Cancer Targeted Therapy market size and forecast at regional and country levels for key market segments covered under the scope North America Cancer Targeted Therapy market trends, as well as market dynamics such as drivers, restraints, and key opportunities North America Cancer Targeted Therapy market analysis covering key trends, regional framework, major players, regulations, and recent market developments Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the North America Cancer Targeted Therapy market Detailed company profiles, including SWOT analysis The geographical scope of the North America Cancer Targeted Therapy market report is divided into: The US, Canada, and Mexico. South North America held the largest share in 2024.
The US dominates the market due to its advanced healthcare infrastructure, high healthcare expenditure, and widespread integration of precision oncology. Hospital pharmacies, academic medical centers, and specialized cancer centers are well-equipped for the administration of monoclonal antibodies, immune checkpoint inhibitors, and ADCs. Genomic profiling and biomarker testing are routinely used to guide therapy decisions, particularly for lung, breast, colorectal, and rare cancers. Government programs—including those under the National Cancer Institute (NCI) and FDA-approved companion diagnostics initiatives—support patient access and clinical research.
Canada represents a smaller yet highly organized market, with public healthcare systems ensuring broad access to oncology therapies. Provinces implement centralized procurement policies for high-cost targeted therapies, with hospital pharmacies serving as the main distribution channel. Canadian hospitals actively participate in global and regional clinical trials, enhancing early adoption of innovative targeted therapies. Reimbursement frameworks ensure equitable access, enabling both common and rare cancer patients to benefit from monoclonal antibodies, tyrosine kinase inhibitors, and immune checkpoint inhibitors.
Overall, both the US and Canada demonstrate high adoption of biomarker-guided therapies, advanced infrastructure, and participation in clinical trials. Hospitals remain the dominant end users, while retail and specialty pharmacies support oral-targeted therapy distribution. Multinational companies maintain a strong presence through partnerships, training programs, and research collaborations. North America's structured healthcare systems, high awareness of precision medicine, and robust clinical trial networks make it the largest and most dynamic market for cancer-targeted therapies globally.
The report includes qualitative and quantitative data in the North America Cancer Targeted Therapy market across therapy type, indication, distribution channel, and geography. The report starts with the key takeaways (chapter 2), highlighting key trends and outlook of the North America Cancer Targeted Therapy market. Chapter 3 includes the research methodology of the study. Chapter 4 includes ecosystem analysis. Chapter 5 highlights the major industry dynamics in the North America Cancer Targeted Therapy market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section. Chapter 6 discusses the North America Cancer Targeted Therapy market scenario, in terms of historical market revenues, and forecast till the year 2031. Chapters 7 to 11 cover North America Cancer Targeted Therapy market segments by therapy type, indication, distribution channel, and geography across the US, Canada, and Mexico. They cover the market revenue, forecast, and factors driving the market. Chapter 12 describes the competitive analysis along with the heat map analysis for the key players operating in the market. Chapter 13 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape. Chapter 14 provides detailed profiles of the major companies operating in the Cancer Targeted Therapy market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments. Chapter 15, i.e., the appendix, is inclusive of a brief overview of the company, a list of abbreviations, and a disclaimer. The North America Cancer Targeted Therapy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the North America cancer targeted therapy market are:
In March 2025, AstraZeneca acquired EsoBiotec to strengthen its CAR-T and cell therapy oncology portfolio. This acquisition enhances precision oncology capabilities, enabling the treatment of rare and advanced cancers. North American hospitals and research centers benefit from access to these novel therapies via clinical trial programs and hospital partnerships. In October 2024, Roche's PIK3CA inhibitor, Inavolisib, was approved for advanced breast cancer, enabling biomarker-guided therapy in North American hospitals. This drug improves treatment precision for patients with specific genetic mutations. World Health Organization (WHO) World Heart Federation (WHF) Organisation for Economic Cooperation and Development (OECD) The World Bank Group Worldometer The Lancet International Bar Association International Trade Administration